Novel approaches to improve prostate cancer diagnosis and management in early-stage disease

BJU International

Volumn 109, Issue SUPPL. 2, 2012, Pages 1-7

  Marberger, Michael ^a   Barentsz, Jelle ^b   Emberton, Mark ^c   Hugosson, Jonas ^d   Loeb, Stacy ^e   Klotz, Laurence ^f   Koch, Michael ^g   Shariat, Shahrokh F ^h   Vickers, Andrew ⁱ  

^a UNIVERSITY OF VIENNA   (Austria)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e NEW YORK UNIVERSITY   (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

active surveillance; biomarkers; biopsy; focal therapy; multi parametric MRI; PSA

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

BIOTECHNOLOGY; CANCER DIAGNOSIS; CANCER FOCAL THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CLINICAL STUDY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; EARLY CANCER; GLEASON SCORE; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; MULTIPARAMETRIC NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; TEMPLATE TRANSPERINEAL PROSTATE MAPPING BIOPSY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GENE;

ANTINEOPLASTIC PROTOCOLS; BIOPSY; CONGRESSES AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MASS SCREENING; PATIENT SELECTION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856164824     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10870.x     Document Type: Conference Paper

References (60)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.10. Lyon, France: International Agency for Research on Cancer 2010. Available from:. Accessed November 2011
2. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
3. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
4. Andriole GL, Crawford ED, Grubb RL 3rd, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
5. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
6. Hugosson J, Carlsson S, Aus G, et al,. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
7. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD,. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138-44 (Pubitemid 26285528)
8. Ries L, Eisner M, Kosary C, et al,. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute, 2005
9. Draisma G, Boer R, Otto SJ, et al,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
10. Gotzsche PC, Nielsen M,. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009; CD001877
11. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L,. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 727-37, W237-42
12. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C,. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-65 (Pubitemid 28395924)
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 3.2011. 2011
14. Klotz L,. Active surveillance for prostate cancer: a review. Curr Urol Rep 2010; 11: 165-71
15. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
16. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM,. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-4
17. Fujita K, Landis P, McNeil BK, Pavlovich CP,. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009; 182: 2664-9
18. van den Bergh RC, Essink-Bot ML, Roobol MJ, et al,. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 115: 3868-78
19. Lee EK, Baack J, Penn H, et al,. Active surveillance for prostate cancer in a veteran population. Can J Urol 2010; 17: 5429-35
20. O'Brien D, Loeb S, Carvalhal GF, et al,. Delay of surgery in men with low risk prostate cancer. J Urol 2011; 185: 2143-7
21. Ross AE, Loeb S, Landis P, et al,. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-6
22. Tosoian JJ, Loeb S, Kettermann A, et al,. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183: 534-8
23. Suardi N, Briganti A, Gallina A, et al,. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 2010; 105: 1548-52
24. Ahmed H, Emberton M,. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol 2008; 26: 457-67
25. Ahmed HU, Freeman A, Kirkham A, et al,. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011; 185: 1246-54
26. Karavitakis M, Winkler MH, Abel PD, Hazell S, Ahmed HU,. Focal therapy for prostate cancer: opportunities and uncertainties. Discov Med 2011; 12: 245-55
27. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI,. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009; 182: 2274-8
28. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO,. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005; 18: 1022-6 (Pubitemid 41224491)
29. Wise AM, Stamey TA, McNeal JE, Clayton JL,. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264-9 (Pubitemid 34831770)
30. Villers A, McNeal JE, Freiha FS, Stamey TA,. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992; 70: 2313-8
31. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM,. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400 (Pubitemid 29190217)
32. Vaidya JS, Joseph DJ, Tobias JS, et al,. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91-102
33. Ahmed HU,. The index lesion and the origin of prostate cancer. N Engl J Med 2009; 361: 1704-6
34. Haffner J, Lemaitre L, Puech P, et al,. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011; 108: E171-8
35. Rouviere O, Girouin N, Glas L, et al,. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 2010; 20: 48-55
36. Sciarra A, Barentsz J, Bjartell A, et al,. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011; 59: 962-77
37. Mullerad M, Hricak H, Kuroiwa K, et al,. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005; 174: 2158-63 (Pubitemid 41611764)
38. Futterer JJ, Heijmink SW, Scheenen TW, et al,. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-58 (Pubitemid 44632891)
39. Futterer JJ, Engelbrecht MR, Huisman HJ, et al,. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005; 237: 541-9 (Pubitemid 41507892)
40. Cirillo S, Petracchini M, Scotti L, et al,. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009; 19: 761-9
41. Lecouvet FE, Geukens D, Stainier A, et al,. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25: 3281-7 (Pubitemid 47325613)
42. Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, et al,. Prostate cancer: local staging at 3-T endorectal MR imaging-early experience 1. Radiology 2006; 238: 184-91 (Pubitemid 43010595)
43. Hambrock T, Somford DM, Huisman HJ, et al,. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-61
44. Zakian KL, Sircar K, Hricak H, et al,. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-14 (Pubitemid 40250824)
45. Hoeks CM, Barentsz JO, Hambrock T, et al,. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66
46. Thompson IM, Ankerst DP, Chi C, et al,. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70 (Pubitemid 41002840)
47. Djavan B, Remzi M, Zlotta AR, et al,. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002; 60: 4-9
48. Ulmert D, Serio AM, O'Brien MF, et al,. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26: 835-41 (Pubitemid 351398073)
49. Vickers AJ, Savage C, O'Brien MF, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
50. O'Brien MF, Cronin AM, Fearn PA, et al,. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 3591-7
51. Stephenson AJ, Kattan MW, Eastham JA, et al,. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-5
52. Fall K, Garmo H, Andren O, et al,. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526-32 (Pubitemid 47073555)
53. Vickers AJ, Wolters T, Savage CJ, et al,. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol 2010; 184: 907-12
54. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al,. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9 (Pubitemid 30004960)
55. de Kok JB, Verhaegh GW, Roelofs RW, et al,. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8 (Pubitemid 34462754)
56. Hessels D, Klein Gunnewiek JM, van Oort I, et al,. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16 (Pubitemid 36741368)
57. Haese A, de la Taille A, van Poppel H, et al,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
58. Hambrock T, Somford DM, Hoeks C, et al,. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183: 520-7
59. NICE Guidelines. Transperineal Template Biopsy and Mapping of the Prostate. 2010. Available from. Accessed November 2011
60. Buckler AJ, Bresolin L, Dunnick NR, et al,. Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology 2011; 259: 875-84